Drawing for CEDNA

USPTO serial 88093870

CEDNA

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
FERRELL, STEVEN WAYNE
Law office
TTAB

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 604: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with CEDNA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

REBECCA LIEBOWITZ

REBECCA LIEBOWITZ VENABLE LLPPO BOX 34385WASHINGTON, DC 20043-9998UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemical preparations, enzymes and DNA for the preparation of nucleic acid for scientific research; chemicals for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; enzymes for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; DNA extracts and cassettes for scientific and research use; DNA extracts for use in agri-biotechnology and nanotechnology other than for medical and veterinary purposes; nucleic acids comprising natural and unnatural nucleotides for use in nanotechnology applications including data storage, data retrieval and computing other than for medical and veterinary purposes; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for use in nanotechnology applications including data storage, data retrieval and computing other than for medical and veterinary purposes; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for use in nanotechnology applications including data storage, data retrieval and computing other than for medical and veterinary purposes; nucleic acid analogues with organic and inorganic chemicals for laboratory use in labeling, imaging and sensing applications; nucleic acid analogues with organic and inorganic chemicals for laboratory use in smart materials; two-dimensional and three-dimensional nucleic acid analogues with organic and inorganic chemicals for laboratory use in creating nanostructures and scaffoldsABANDONED—
005Vaccines; DNA based vaccines; DNA extracts, namely, nucleic acid sequences and chemical reagents for medical use; therapeutic DNA, namely, nucleic acid sequences and chemical reagents for medical and veterinary purposes; nucleic acids comprising natural and unnatural nucleotides for medical and veterinary purposes; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for medical and veterinary purposes; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in labeling, imaging and sensing applications; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in smart materials; two-dimensional and three-dimensional nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in creating nanostructures and scaffoldsABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 22, 2020MAB4ABANDONMENT NOTICE E-MAILED - INTER PARTES DECISION—
Oct 22, 2020ABN4ABANDONMENT - AFTER INTER PARTES DECISION—
Oct 22, 2020OP.TOPPOSITION TERMINATED NO. 999999—
Oct 22, 2020OP.SOPPOSITION SUSTAINED NO. 999999—
Sep 7, 2019EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Sep 5, 2019OP.IOPPOSITION INSTITUTED NO. 999999—
Sep 5, 2019OPPFOPPOSITION PAPERS RECEIVED AT TTAB—
Aug 6, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 6, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 17, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 27, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 22, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 22, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 19, 2019PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jun 17, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 17, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 15, 2019ALIEASSIGNED TO LIE—
Jun 11, 2019TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jun 11, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 11, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 11, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 11, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 11, 2018DOCKASSIGNED TO EXAMINER—
Sep 6, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 30, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance